Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY GEORGE MCCAUL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1295701522
CMS profile
194337
Location
SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$91,414.09

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Therakos LLC $29,831.66 25
Incyte Corporation $26,952.34 38
Janssen Biotech, Inc. $20,471.95 19
Karyopharm Therapeutics Inc. $13,562.50 10
E.R. Squibb & Sons, L.L.C. $455.00 1
Daiichi Sankyo Inc. $85.25 4
Merck Sharp & Dohme LLC $33.28 1
Rigel Pharmaceuticals, Inc. $22.11 1

Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY GEORGE MCCAUL

NPI 1295701522 · CMS profile ID 194337

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 99 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295701522?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $91,414.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $1,370.0011/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225971494 CMS
Karyopharm Therapeutics Inc. $1,550.0011/10/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246647664 CMS
Therakos LLC $7,980.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1228219324 CMS
Therakos LLC $5,985.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1228219352 CMS
Daiichi Sankyo Inc. $26.6310/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197037211 CMS
Incyte Corporation $685.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226141295 CMS
Therakos LLC $17.9610/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219354 CMS
Therakos LLC $17.3610/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219362 CMS
Therakos LLC $5.5710/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219364 CMS
Therakos LLC $458.8610/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219366 CMS
Therakos LLC $126.0010/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219350 CMS
Therakos LLC $14.9610/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219356 CMS
Therakos LLC $26.7710/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219358 CMS
Therakos LLC $62.0010/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219360 CMS
Therakos LLC $181.7410/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219368 CMS
Therakos LLC $121.8710/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219322 CMS
Therakos LLC $15.0010/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219326 CMS
Therakos LLC $19.9410/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219328 CMS
Therakos LLC $17.9710/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219330 CMS
Therakos LLC $366.8210/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219332 CMS
Therakos LLC $264.4210/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219334 CMS
Karyopharm Therapeutics Inc. $1,550.0009/23/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246647656 CMS
Therakos LLC $6,650.0009/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1228219336 CMS
Therakos LLC $26.9109/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219338 CMS
Therakos LLC $48.9409/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219340 CMS
Karyopharm Therapeutics Inc. $387.5009/12/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246647660 CMS
Therakos LLC $34.6409/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219342 CMS
Therakos LLC $22.5609/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228219344 CMS
Therakos LLC $22.0009/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219346 CMS
Therakos LLC $694.3709/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1228219348 CMS
Janssen Biotech, Inc. $941.9708/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174799107 CMS
Janssen Biotech, Inc. $4,162.5008/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174801353 CMS
Janssen Biotech, Inc. $90.4808/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174800070 CMS
Janssen Biotech, Inc. $416.2508/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174801245 CMS
Therakos LLC $6,650.0007/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1228219320 CMS
Karyopharm Therapeutics Inc. $1,550.0007/22/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246647649 CMS
Daiichi Sankyo Inc. $21.9907/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197084509 CMS
Janssen Biotech, Inc. $5.5007/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174799964 CMS
Janssen Biotech, Inc. $5.5007/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174799116 CMS
Incyte Corporation $4,795.0006/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226041870 CMS
Daiichi Sankyo Inc. $17.3006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197078503 CMS
Incyte Corporation $5,480.0006/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226171311 CMS
Karyopharm Therapeutics Inc. $1,550.0006/03/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1246647653 CMS
Janssen Biotech, Inc. $1,130.6705/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174800346 CMS
Janssen Biotech, Inc. $850.6305/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174799590 CMS
Janssen Biotech, Inc. $4,162.5005/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174798632 CMS
E.R. Squibb & Sons, L.L.C. $455.0005/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184496152 CMS
Janssen Biotech, Inc. $124.9905/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174799832 CMS
Incyte Corporation $33.5205/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226041714 CMS
Incyte Corporation $54.8505/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226041894 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $253,460.09 219
PY2020 $141,956.74 99
PY2021 $204,771.35 167
PY2022 $251,779.21 196
PY2023 $179,333.96 180
PY2024 $114,551.44 114
PY2025 $91,414.09 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $17,061.66 2
PY2022 Principal investigator $4,880.00 5
PY2021 Principal investigator $12,693.30 2
PY2020 Principal investigator $47,256.65 21
PY2019 Recipient $935.00 1
PY2019 Principal investigator $188,118.29 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Celgene Corporation $935.00 12/09/2019 Covered Recipient Physician A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) No dispute reported 06/30/2026 675414177
Principal investigator 1 Celgene Corporation $2,219.10 11/21/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) No dispute reported 06/30/2026 675414591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.74 11/20/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161181
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $198.61 11/19/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161183
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 11/13/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,746.00 11/05/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $287.39 10/08/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161179
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $109.83 09/17/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686159599
Principal investigator 1 Janssen Research & Development, LLC $1,309.00 09/16/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 654235577
Principal investigator 1 Janssen Research & Development, LLC $11,112.00 09/09/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 654235575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $262.32 09/09/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686159597
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/02/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 654235579
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $198.61 08/13/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686159601
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $524.64 08/12/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161273
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/29/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 654235573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.77 07/16/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686159603
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $198.49 07/16/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686159605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $873.00 07/16/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $198.49 07/16/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161267
Principal investigator 1 Janssen Research & Development, LLC $366.00 06/25/2019 Non-covered Recipient Entity
Avera Mckennan
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant No dispute reported 06/30/2026 654243375
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/25/2019 Non-covered Recipient Entity
Avera Mckennan
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant No dispute reported 06/30/2026 654243377
Principal investigator 1 Janssen Research & Development, LLC $178.00 06/14/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 654235589
Principal investigator 1 Janssen Research & Development, LLC $2,986.00 06/14/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 654235591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $326.07 05/29/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $436.50 05/29/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161281
Principal investigator 1 Incyte Corporation $500.00 05/23/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666518193
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,619.00 05/07/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161271
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 05/07/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161279
Principal investigator 1 Amgen Inc. $7,662.00 05/03/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
P3 Multiple Myeloma Frontline No dispute reported 06/30/2026 675779065
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 04/29/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 654235583
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 04/16/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AC220-007 No dispute reported 06/30/2026 688839395
Principal investigator 1 Janssen Research & Development, LLC $450.00 04/15/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 654235585
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $1,000.00 04/04/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
PCYC-1141-CA No dispute reported 06/30/2026 673107555
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 04/01/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 654235587
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 03/28/2019 Non-covered Recipient Entity
Avera Mckennan
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant No dispute reported 06/30/2026 654243373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $436.50 03/26/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161185
Principal investigator 1 Janssen Research & Development, LLC $1,802.00 03/18/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 654235593
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/15/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma No dispute reported 06/30/2026 654235581
Principal investigator 1 Amgen Inc. $1,048.00 03/06/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
P3 Multiple Myeloma Frontline No dispute reported 06/30/2026 675779063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196.74 03/04/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161277
Principal investigator 1 Celgene Corporation $37,590.51 02/14/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence (ACE-536-MF-001) No dispute reported 06/30/2026 675414607
Principal investigator 1 Incyte Corporation $887.40 02/05/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666518151
Principal investigator 1 Celgene Corporation $34,305.00 02/01/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) No dispute reported 06/30/2026 675414593
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,782.22 01/29/2019 Non-covered Recipient Entity
AVERA MCKENNAN d b a
TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom No dispute reported 06/30/2026 686161275
Principal investigator 1 Incyte Corporation $53.70 01/28/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666518187
Principal investigator 1 Incyte Corporation $286.40 01/28/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 666518189
Principal investigator 1 Janssen Research & Development, LLC $2,706.25 01/24/2019 Non-covered Recipient Entity
Avera Mckennan
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant No dispute reported 06/30/2026 654243371
Principal investigator 1 Celgene Corporation $14,733.46 01/16/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (MEDI4736-MDS-001) No dispute reported 06/30/2026 675414601
Principal investigator 1 Celgene Corporation $443.22 01/07/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) No dispute reported 06/30/2026 675414595
Principal investigator 1 Celgene Corporation $38,294.33 01/03/2019 Covered Recipient Teaching Hospital
AVERA MCKENNAN
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (MEDI4736-MDS-001) No dispute reported 06/30/2026 675414599